Impact of retinol binding protein 4 polymorphism on rosiglitazone response in Chinese Type 2 diabetic patients
10.3969/j.issn.1672-7347.2011.10.004
- VernacularTitle:视黄醇结合蛋白4基因多态性对中国2型糖尿病患者服用罗格列酮疗效的影响
- Author:
Fang ZHOU
;
Qiong HUANG
;
Xingping DAI
;
Jiye YIN
;
Jing WU
;
Honghao ZHOU
;
Zhicheng GONG
;
Zhaoqian LIU
- Publication Type:Journal Article
- Keywords:
retinol binding protein 4;
polymorphism;
Type 2 diabetes mellitus;
rosiglitazone;
therapeutic efficacy
- From:
Journal of Central South University(Medical Sciences)
2011;36(10):949-957
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the association between rs3758539G-803A and rs10882283 T-179G polymorphism of retinol binding protein 4 (RBP4) and rosiglitazone response in Chinese type 2 diabetes mellitus (T2DM) patients.Methods A total of 472 Chinese T2DM patients and 198 healthy subjects were enrolled to identify G-803A and T-179G genotypes using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP ).assay.Forty-two T2DM patients with different G-803A or T-179G genotypes were selected to undergo a 12-week rosiglitazone treatment (4 mg/d).Serum fasting plasma glucose (FPG),postprandial plasma glucose (PPG),fasting serum insulin (FINS),glycated hemoglobin (HbAlc),postprandial serum insulin ( PINS),triglyceride (TG),low-density lipoprotein-cholesterol ( LDL-c),and high-density lipoprotein-cholesterol (HDL-c) were determined before and after the rosiglitazone treatment.Results T2DM patients with RBP4 G-803A GG genotype showed lower TG and LDL-c concentrations compared with that in the GA +AA genotype subjects.T2DM patients with RBP4 T-179G TT genotype showed lower waist-to-hip ratio (WHR),FPG and FINS values compared with that in the TG + GG genotype individuals.Patients with GG genotype of RBP4 G-803A had an enhanced rosiglitazone efficacy on FPG and FINS compared with that in the GA + AA genotype group.Patients with RBP4 T179G TG + GG genotype showed an enhanced rosiglitazone efficacy on HbAlc level compared with that in the TT genotype group.Conclusion RBP4 G-803A and T-179G polymorphism might be associated with the development of T2DM and affect the therapeutic efficacy of rosignitazone in Chinese T2DM patients.
